Project Grant HT9425261E356
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles (UCLA) $799,999 through the Military Medical Research and Development program (CFDA 12.420) for the project "From H&E to HRD: Linking Morphometry, Clinical, and Molecular Data for Drug Response Prediction." The award, effective May 1, 2026, through April 30, 2030, supports UCLA's research initiatives conducted at its Los Angeles facility. This project falls within the...
- Federal Grant Award Summary The University of California, Los Angeles (UCLA) received a $551,216 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2027. The grant funds research to elucidate the functional role of PPP1R1B-lncRNA in myocyte repair in Duchenne muscular dystrophy (DMD). This research initiative represents a hypothesis-driven investigation into therapeutic...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Los Angeles (UCLA) a Project Grant totaling $7.35 million on August 1, 2025, under the Military Medical Research and Development program (CFDA 12.420) to conduct a clinical evaluation of 4-aminopyridine in hereditary spinocerebellar ataxia. The two-year award, with a completion date of July 31, 2027, supports research conducted at UCLA's Los Angeles campus through the institution's Office of...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles (UCLA) a $590,625 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. This pilot study investigates dual immunotherapy combining programmed cell death protein 1 (PD-1) and CD73 inhibitors with chemotherapy in patients with pancreatic adenocarcinoma, with specific focus on identifying immune mechanisms...
- This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles (UCLA) a $2.076 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2030. The research project, titled "Defining an Error-Free DNA Repair Signature as a Predictive Marker for Lethal Prostate Cancer," will be conducted at UCLA's Los Angeles, California campus through the Office of...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $2.16M Project Grant on September 30, 2025, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on cerebellar neuromodulation to reduce cognitive dysfunction after multiple subconcussive impacts. The four-year project, scheduled for completion on September 29, 2029, will be performed at UCLA's Los Angeles campus through the Office of Research Administration. This award supports...
- Federal Project Grant Award Summary The Defense Health Agency (DHA), through its Military Medical Research and Development program (CFDA 12.420), awarded a $157,500 Project Grant to the University of California, Los Angeles (UCLA) Office of Research Administration, effective September 1, 2025, with completion scheduled for August 31, 2026. The award supports research investigating the impact of a hypomorphic SMARCB1 germline allele specific for schwannomatosis on mouse development and...
- Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $1.75 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2029. The research initiative, titled "Deconstructing AAV-Associated Liver Toxicity: Biomarkers and Immune Insights to Enable Safer Gene Therapies," will be conducted at UCLA's Los Angeles campus. This project delivers biomedical research services focused on identifying...